-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The continuous growth of diabetic patients has created a huge market demand for diabetes drugs.
According to the Frost & Sullivan report, the total market size of type 2 diabetes alone in the world is close to US$70 billion
.
It is understood that in the diabetes drug market, companies are also continuously strengthening their layout to meet the broad market demand
.
For example, Acarbose Tablets of Deyuan Pharmaceutical, a pharmaceutical company listed on the Beijing Stock Exchange, has recently obtained a drug registration certificate issued by the State Food and Drug Administration, which is deemed to have passed the consistency evaluation
.
Acarbose tablet is a kind of diabetes drug, which can delay the hydrolysis of starch and other polysaccharide compounds in the body, control the postprandial blood sugar level, and reduce the effect of glycosylated hemoglobin.
, the annual sales amounted to 7.
644 billion yuan
.
Deyuan Pharmaceutical stated that the acquisition of the drug registration certificate for acarbose tablets this time has further enriched the company's product pipeline in the field of diabetes, and formed a synergistic effect with existing products in the field of diabetes, consolidating and enhancing the company's brand in the field of diabetes.
effect and market competitiveness
.
According to the industry, the market space for acarbose tablets is considerable, but there are not many companies that can provide medicines
.
At present, only 11 domestic enterprises including Shandong Lukang Pharmaceutical Co.
, Ltd.
and Guizhou Shengjitang Pharmaceutical Co.
, Ltd.
have passed or are deemed to have passed the consistency evaluation
.
With the continuous listing of hypoglycemic drugs, patients will also have more choices
.
In addition to the above-mentioned companies, Kelun Pharmaceutical has also released new news recently.
According to its announcement, Kelun Pharmaceutical's chemical drug "Lingagliptin Tablets" has recently been approved by the State Drug Administration for drug registration
.
It is reported that linagliptin is a DPP-4 inhibitor that does not need to adjust the dose according to the patient's liver and kidney function status.
advantage
.
In the field of hypoglycemic competition, various pharmaceutical companies are competing to release new news
.
It is reported that Hengrui Medicine also recently issued an announcement saying that the Class 1 chemical drug Proline Henggliflozin Tablets has been approved for marketing, becoming my country's currently approved domestic innovative SGLT2 inhibitor
.
Up to now, Hengrui has invested about 270 million yuan in research and development in related projects of Proline Henggliflozin
.
In addition, Nanjing Chia Tai Tianqing has recently entered the administrative approval stage for sitagliptin metformin sustained-release tablets, which are imitated Class 3, and is expected to be approved for marketing in the near future
.
In order to better seize the market, many companies are competing in the field of diabetes medication
.
For another example, Paige Biosciences stated that taking diabetes as an entry point into the chronic disease market, through product combination, it has developed two innovative products, PB-119 and PB-201, with different targets and different mechanisms of action
.
These two products meet the treatment needs of different diabetic patients and expand the market space of the products
.
Huadong Medicine has continued to make efforts in the field of diabetes medication.
In recent years, its research and development products have gradually expanded to compound preparations, SGLT-2 inhibitors, GLP-1 receptor agonists, insulin and its analogs
.
It is reported that China East China recently submitted its second new drug clinical application for insulin products
.
Affected by the aging of the population, the improvement of living standards and unhealthy life>
.
Data show that in 2020, China's diabetes drug market will exceed 52 billion yuan
.
In the face of the huge market for diabetes drugs, many pharmaceutical companies are competing for the layout, and the market competition also appears to be quite fierce
.
It is understood that the common clinical diabetes drugs mainly include insulin and its analogs, oral hypoglycemic drugs and GLP-1 receptor agonists
.
Among them, chemical oral hypoglycemic drugs mainly include: sulfonylureas, non-sulfonylurea insulin secretagogues, biguanides, α-glucosidase inhibitors, thiazolidinediones (TZDs), incretin and DPP- 4 Inhibitors, SGLT-2 inhibitors
.
According to the Frost & Sullivan report, the total market size of type 2 diabetes alone in the world is close to US$70 billion
.
It is understood that in the diabetes drug market, companies are also continuously strengthening their layout to meet the broad market demand
.
For example, Acarbose Tablets of Deyuan Pharmaceutical, a pharmaceutical company listed on the Beijing Stock Exchange, has recently obtained a drug registration certificate issued by the State Food and Drug Administration, which is deemed to have passed the consistency evaluation
.
Acarbose tablet is a kind of diabetes drug, which can delay the hydrolysis of starch and other polysaccharide compounds in the body, control the postprandial blood sugar level, and reduce the effect of glycosylated hemoglobin.
, the annual sales amounted to 7.
644 billion yuan
.
Deyuan Pharmaceutical stated that the acquisition of the drug registration certificate for acarbose tablets this time has further enriched the company's product pipeline in the field of diabetes, and formed a synergistic effect with existing products in the field of diabetes, consolidating and enhancing the company's brand in the field of diabetes.
effect and market competitiveness
.
According to the industry, the market space for acarbose tablets is considerable, but there are not many companies that can provide medicines
.
At present, only 11 domestic enterprises including Shandong Lukang Pharmaceutical Co.
, Ltd.
and Guizhou Shengjitang Pharmaceutical Co.
, Ltd.
have passed or are deemed to have passed the consistency evaluation
.
With the continuous listing of hypoglycemic drugs, patients will also have more choices
.
In addition to the above-mentioned companies, Kelun Pharmaceutical has also released new news recently.
According to its announcement, Kelun Pharmaceutical's chemical drug "Lingagliptin Tablets" has recently been approved by the State Drug Administration for drug registration
.
It is reported that linagliptin is a DPP-4 inhibitor that does not need to adjust the dose according to the patient's liver and kidney function status.
advantage
.
In the field of hypoglycemic competition, various pharmaceutical companies are competing to release new news
.
It is reported that Hengrui Medicine also recently issued an announcement saying that the Class 1 chemical drug Proline Henggliflozin Tablets has been approved for marketing, becoming my country's currently approved domestic innovative SGLT2 inhibitor
.
Up to now, Hengrui has invested about 270 million yuan in research and development in related projects of Proline Henggliflozin
.
In addition, Nanjing Chia Tai Tianqing has recently entered the administrative approval stage for sitagliptin metformin sustained-release tablets, which are imitated Class 3, and is expected to be approved for marketing in the near future
.
In order to better seize the market, many companies are competing in the field of diabetes medication
.
For another example, Paige Biosciences stated that taking diabetes as an entry point into the chronic disease market, through product combination, it has developed two innovative products, PB-119 and PB-201, with different targets and different mechanisms of action
.
These two products meet the treatment needs of different diabetic patients and expand the market space of the products
.
Huadong Medicine has continued to make efforts in the field of diabetes medication.
In recent years, its research and development products have gradually expanded to compound preparations, SGLT-2 inhibitors, GLP-1 receptor agonists, insulin and its analogs
.
It is reported that China East China recently submitted its second new drug clinical application for insulin products
.
Affected by the aging of the population, the improvement of living standards and unhealthy life>
.
Data show that in 2020, China's diabetes drug market will exceed 52 billion yuan
.
In the face of the huge market for diabetes drugs, many pharmaceutical companies are competing for the layout, and the market competition also appears to be quite fierce
.
It is understood that the common clinical diabetes drugs mainly include insulin and its analogs, oral hypoglycemic drugs and GLP-1 receptor agonists
.
Among them, chemical oral hypoglycemic drugs mainly include: sulfonylureas, non-sulfonylurea insulin secretagogues, biguanides, α-glucosidase inhibitors, thiazolidinediones (TZDs), incretin and DPP- 4 Inhibitors, SGLT-2 inhibitors
.
